Bad News for Allergan--and First-To-File Plaintiffs--in Delaware Derivative Ruling

, The Litigation Daily


After Gibson Dunn knocked out a derivative suit over Allergan's Botox marketing six months ago, the company and its board hoped the litigation had been put to rest. But Vice Chancellor J. Travis Laster of the Delaware Court of Chancery dashed those hopes on Monday--in an decision that's sure to have lawyers in both the defense and plaintiffs bar gnashing their teeth.

This article has been archived, and is no longer available on this website.

View this content exclusively through LexisNexis® Here

Not a LexisNexis® Subscriber?

Subscribe Now

Why am I seeing this?

LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via® and Nexis®. This includes content from The National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.

ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.

For questions call 1-877-256-2472 or contact us at

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article# 1202559190066

Thank you!

This article's comments will be reviewed.